Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201606-02 Development of long-acting conjugation factor VIIa fusion proteins by next generation of NexPTM technology(Hematological Diseases, Protein) [11.01.2016]

PRINT

Development and Market Objectives

Development of best-in-class long-acting coagulation factor VIIa candidates based on next generation of NexPTM technology that maintain biological activity and exhibit prolonged half-life in vivo through 1) establishment of stable cell lines 2) optimization of cell culture processes 3) establishment of purification processes

Unmet Medical Need & Target Patients

Target patients: patients with hemophilia A or B with inhibitors to factor VIII or factor IX that need commercially-available factor VIIa treatment

Unmet medical need

- Short in vivo half-life: ~2 hours in human (NovoSeven®)

- High frequency of use for the patients (NovoSeven®)

- No approved drug for prophylactic treatment

Status

We have acquired the technology for efficient gamma-carboxylation and activation as well as high productivity, which are crucial for development of recombinant factor VIIa.

- 7 times increase of half-life compared to NovoSeven® (in rats)

- Coagulation activity comparable to NovoSeven® (in rats)

- Development of FVIIa-NexP with next generation of NexP technology

Intellectual Property

- Two patent applications on the platform technology of NexP: submitted for 13 countries, registered in 9 countries including US and Europe  

- Korean patents and PCT applications in preparation.

Competitive Advantages

- No approved long-acting recombinant FVIIa: only three candidates are under clinical trials

- Higher half-life of FVIIa-NexP over albumin- or CTP-fusion FVIIa (in rats)

- Better long-acting coagulation property of FVIIa-NexP than FVIIa-CTP fusion.

- Significantly improved productivity in culture and purification process

Indication

Hemophilia

Research Period

2016.10.1-2018.9.30

Company

Alteogen, Inc.

Developmental Stage

Optimization

Additional Information

Contact Information

Contact
Address Company Name: Alteogen, Inc.
WebSite Homepage: http://www.alteogen.com Contact Person: Jaehyeong Ko, Ph.D.
E-mail: jhko@alteogen.com Contact: +82-42-867-8785

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code